文献速递神经免疫

瑞典全国队列:奥瑞利珠单抗与利妥昔单抗在多发性硬化中感染风险相当

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study.
PubMed 文献 · Ann Neurol · 2026-06-17

该瑞典全国队列纳入2014至2025年间16,872个利妥昔单抗、奥瑞利珠单抗或其他疾病修正治疗(DMT)的治疗 episode,评估感染风险与复发结局。两种抗CD20药物感染率均高于其他DMT,但复发率显著更低;利妥昔单抗与奥瑞利珠单抗之间感染和复发风险相似。

要点

  • 抗CD20药物感染率高于其他DMT,但复发率显著更低。
  • 利妥昔单抗与奥瑞利珠单抗的感染和复发风险相似。
  • 选择两种抗CD20药物时感染风险非关键区分因素。

核心结论

  • 利妥昔单抗与奥瑞利珠单抗在多发性硬化中的感染风险和复发风险相似。

研究设计与样本

  • 全国性队列研究,纳入2014至2025年间16,872个利妥昔单抗、奥瑞利珠单抗或其他DMT的治疗episode。

主要发现

  • 利妥昔单抗和奥瑞利珠单抗的感染率均高于其他DMT。
  • 利妥昔单抗和奥瑞利珠单抗的复发率均显著低于其他DMT。
  • 利妥昔单抗与奥瑞利珠单抗之间感染风险和复发风险相似。

关键数值与推荐

  • 感染结局包括严重感染、住院诊断感染和抗生素使用;复发风险作为疗效标志评估。

临床怎么用

  • 临床选择利妥昔单抗或奥瑞利珠单抗时,感染风险差异不大,可综合其他因素决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In multiple sclerosis (MS), anti-CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease-modifying therapies (DMTs) between 2014 and 2025. Infection outcomes included serious infections, hospital-diagnosed infections, and antibiotic use, and relapse risk was assessed as a marker of efficacy. Both rituximab and ocrelizumab were associated with higher infection rates than other DMTs, while relapse rates were substantially lower. Infection and relapse risks were similar between rituximab and ocrelizumab. ANN NEUROL 2026;100:788-792.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Frisell T, Hedberg S, Piehl F, et al. Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Ann Neurol. 2026. PMID: 42310849. doi:10.1002/ana.78286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。